Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years

被引:7
|
作者
Ye, Yanna [1 ,2 ]
Li, Zhiqiang [1 ]
Kang, Shan [3 ]
Zhan, Xuemei [4 ]
Zhang, Yi [5 ]
Xu, Yan [6 ]
Li, Weili [2 ]
Lang, Jinghe [2 ,7 ]
Liu, Ping [2 ]
Chen, Chunlin [1 ,2 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 Guangzhou Ave, Guangzhou 510515, Peoples R China
[2] Dongguan Polytech, Fac Hlth, Dept Midwifery, Dongguan, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Gynecol, Shijiazhuang, Peoples R China
[4] SEN Univ, Affiliated Jiangmen Hosp SUN YAT, Dept Obstet & Gynecol, Jiangmen, Peoples R China
[5] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Peoples R China
[6] Pan Yu Cent Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
cervical cancer; disease-free survival; intermediate-risk pathological factor; oncological outcome; overall survival; postoperative adjuvant therapy; RADICAL HYSTERECTOMY; PELVIC IRRADIATION; RADIATION-THERAPY; RANDOMIZED-TRIAL; CARCINOMA; CHEMOTHERAPY; IB; RADIOTHERAPY; CISPLATIN; METASTASIS;
D O I
10.1111/jog.15632
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early-stage cervical cancer (ECC) patients with one intermediate-risk pathological factor (IPF).Methods: A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan-Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease-free survival (DFS) among the three groups, before and after propensity score matching (PSM).Results: The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan-Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5-year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post-hoc tests yielded similar results, with no differences in 5-year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).Conclusion: Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.
引用
下载
收藏
页码:1579 / 1591
页数:13
相关论文
共 50 条
  • [1] Impact of Adjuvant Radiotherapy on Survival Outcomes in Intermediate-Risk, Early-Stage Cervical Cancer: Analyses Regarding Surgical Approach of Radical Hysterectomy
    Kim, Se Ik
    Kim, Tae Hun
    Lee, Maria
    Kim, Hee Seung
    Chung, Hyun Hoon
    Lee, Taek Sang
    Jeon, Hye Won
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong Sang
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 11
  • [2] Impact of adjuvant radiotherapy on survival outcomes in intermediate-risk, early-stage cervical cancer: analyses regarding surgical approach of radical hysterectomy
    Kim, Se Ik
    Kim, Tae Hun
    Lee, Maria
    Kim, Jae-Weon
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S174 - S175
  • [3] Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer
    Cao, Lijie
    Wen, Hao
    Feng, Zheng
    Han, Xiaotian
    Zhu, Jun
    Wu, Xiaohua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 52 - 58
  • [4] Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer
    Matsuo, Koji
    Shimada, Muneaki
    Matsuzaki, Shinya
    Machida, Hiroko
    Shigeta, Shogo
    Yoshida, Hiroshi
    Kato, Kazuyoshi
    Kanao, Hiroyuki
    Takekuma, Munetaka
    Mikami, Mikio
    Okamoto, Aiko
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,
  • [5] Adenocarcinoma as an independent risk factor for early-stage intermediate-risk cervical carcinoma
    Mathews, C.
    Goodrich, S.
    Farrell, R.
    DeSimone, C.
    Seamon, L.
    Landrum, L.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S104 - S105
  • [6] Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy in early-stage cervical cancer patients with intermediate risk factors
    Yu, Hao
    Zhang, Linlin
    Du, Xuelian
    Sheng, Xiugui
    ONCOTARGETS AND THERAPY, 2016, 9 : 7331 - 7335
  • [7] Management of patients with intermediate-risk early stage cervical cancer
    Cibula, David
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (03)
  • [8] Survival benefit of postoperative adjuvant chemotherapy for patients in poor-differentiated early-stage cervical cancer: A multicenter, cohort study.
    Lu, Huaiwu
    Xu, Miaochun
    Zhou, Ying
    Zhao, Bingbing
    Ren, Fang
    Wei, Luwei
    Chen, Qing
    Zhang, Bingzhong
    Lin, Zhongqiu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17509 - E17509
  • [9] PREDICTORS OF RECURRENCE IN SURGICALLY STAGED INTERMEDIATE-RISK EARLY-STAGE CERVICAL CANCER
    Artuso, Valeria
    Meschini, Tommaso
    Schivardi, Gabriella
    Antonio De Vitis, Luigi
    Multinu, Francesco
    Martin-Calvo, Nerea
    Chiva, Luis
    Ghezzi, Fabio
    Casarin, Jvan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A87 - A88
  • [10] Delayed adjuvant radiotherapy in early-stage cervical cancer with intermediate-risk features has a detrimental effect on survival that cannot be corrected by adjuvant chemotherapy.
    Kodiyan, Joyson
    Guirguis, Adel
    Ashmalla, Hani
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)